Semax
Neurological Research Peptide
Size: 5mg
With code FALL
Stacks with code FALL
Semax is a synthetic ACTH(4-10) analog (Met-Glu-His-Phe-Pro-Gly-Pro) studied for neuroprotective and cognitive-signaling effects in research models.
Semax (ACTH 4-10 Analog)
Synthetic heptapeptide analog of the ACTH(4-10) fragment (MEHFPGP)
Developed within Russian neuropeptide research
Studied for neuroprotective and nootropic signaling
Investigated for BDNF and NGF expression in models
Referenced in cognition and cerebral-ischemia research
Research Use Notes
Supplied as lyophilized powder
Requires reconstitution before use
Research Water required for mixing (sold separately)
Swirl gently, never shake
Storage
Store lyophilized vial frozen for long-term holding
Keep reconstituted solution at 2 to 8°C
Protect from light and heat
Handling
Maintain sterile technique throughout reconstitution
For laboratory research use only
Avoid repeated freeze-thaw cycles to preserve integrity
Certificate of Analysis
Independently 8x Tested by Kovera Labs and/or ILS Labs
(Click here to learn about 8x testing)
All certificates are issued by independent ISO-accredited laboratories. Lot-specific documents are made available to qualified research professionals on request.
Frequently Bought Together
Commonly paired to support consistent, reliable experimentation.
BPC-157
$60$42With code FALLTissue Repair Peptide
Compound Information
Technical specifications
What Is Semax?
ACTH (4-10) analog · Met-Glu-His-Phe-Pro-Gly-Pro
- Type
- Synthetic peptide (ACTH 4-10 analog)
- CAS Number
- 80714-61-0
- Molecular Weight
- 813.9 g/mol
- Amino Acids
- 7
Stability Information
-20°C
24+ months
2-8°C
~30 days
Sources & References
Peer-reviewed research
Products are intended solely for laboratory and scientific research purposes. Not intended for human consumption, veterinary use, diagnosis, treatment, cure, or prevention of disease.
All the research compounds you need, with the confidence that every batch is 8× tested before it ships.
Subscribe to our Newsletter
Subscribe to our newsletter to get daily insights, news, updates.